N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults

被引:440
作者
Kistorp, C
Raymond, I
Pedersen, F
Gustafsson, F
Faber, J
Hildebrandt, P
机构
[1] Frederiksberg Univ Hosp, Dept Cardiol & Endocrinol, DK-2000 Copenhagen, Denmark
[2] Rigshosp, Dept Cardiol, DK-2100 Copenhagen, Denmark
[3] Herlev Univ Hosp, Dept Endocrinol, DK-2730 Herlev, Denmark
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2005年 / 293卷 / 13期
关键词
D O I
10.1001/jama.293.13.1609
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context B-type natriuretic peptides have been shown to predict cardiovascular disease in apparently healthy individuals but their predictive ability for mortality and future cardiovascular events compared with C-reactive protein (CRP) and urinary albumin/creatinine ratio is unknown. Objective To assess the prognostic value of the N-amino terminal fragment of the prohormone brain natriuretic peptide (NT-proBNP) vs CRP and urinary albumin/creatinine ratio in an older adult population. Design, Setting, and Participants A population-based prospective study of 764 participants aged 50 to 89 years from a community in Copenhagen, Denmark, in which 658 participants provided blood and urinary samples and were examined between September 1, 1998, and January 24, 2000. Of these participants, 626 without heart or renal failure were enrolled. A subgroup of 537 had no history of cardiovascular disease at baseline. During 5 years of follow-up (to December 31, 2003), 94 participants died and 65 developed a first major cardiovascular event. Main Outcome Measures Risk of mortality and first major cardiovascular event by baseline levels of NT-proBNP, CRP, and urinary albumin/creatinine ratio levels. Results After adjustment for the cardiovascular risk factors of age, sex, smoking, diabetes mellitus, hypertension or ischemic heart disease, total cholesterol, and serum creatinine, the hazard ratio (HR) of mortality for values above the 80th percentile of NT-proBNP was 1.96 (95% confidence interval [CI], 1.21-3.19); for CRP, 1.46 (95% CI, 0.89-2.24); and for urinary albumin/creatinine ratio, 1.88 (95% CI, 1.18-2.98). Additional adjustment for left ventricular systolic dysfunction did not markedly attenuate the predictive value of NT-proBNP (HR, 1.82; 95% CI, 1.11-2.98). The absolute unadjusted increase in mortality risk for participants with values above the 80th percentile vs equal to or below the 80th percentile was 24.5% for NT-proBNP, 7.8% for CRP, and 19.5% for urinary albumin/creatinine ratio. The NT-proBNP levels were associated with first major cardiovascular events (nonfatal myocardial infarction, fatal coronary heart disease, unstable angina, heart failure, stroke, and transient ischemic attack) with an adjusted HR of 3.24 (95% CI, 1.80-5.79) vs 1.02 (95% CI, 0.56-1.85) for CRP and 2.32 (95% CI, 1.33-4.05) for urinary albumin/creatinine ratio when comparing participants with values above the 80th percentile with those with values equal to or below the 80th percentile. Conclusions Measurements of NT-proBNP provide prognostic information of mortality and first major cardiovascular events beyond traditional risk factors. NT-proBNP was a stronger risk biomarker for cardiovascular disease and death than CRP was in nonhospitalized individuals aged 50 to 89 years.
引用
收藏
页码:1609 / 1616
页数:8
相关论文
共 45 条
[21]   Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population [J].
McDonagh, TA ;
Cunningham, AD ;
Morrison, CE ;
McMurray, JJV ;
Ford, I ;
Morton, JJ ;
Dargie, HJ .
HEART, 2001, 86 (01) :21-26
[22]   C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men [J].
Mendall, MA ;
Strachan, DP ;
Butland, BK ;
Ballam, L ;
Morris, J ;
Sweetnam, PM ;
Elwood, PC .
EUROPEAN HEART JOURNAL, 2000, 21 (19) :1584-1590
[23]   Plasma levels of A- and B-type natriuretic peptides in patients with hypertrophic cardiomyopathy or idiopathic dilated cardiomyopathy [J].
Mizuno, Y ;
Yoshimura, M ;
Harada, E ;
Nakayama, M ;
Sakamoto, T ;
Shimasaki, Y ;
Ogawa, H ;
Kugiyama, K ;
Saito, Y ;
Nakao, K ;
Yasue, H .
AMERICAN JOURNAL OF CARDIOLOGY, 2000, 86 (09) :1036-1040
[24]   N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes [J].
Omland, T ;
Persson, A ;
Ng, L ;
O'Brien, R ;
Karlsson, T ;
Herlitz, J ;
Hartford, M ;
Caidahl, K .
CIRCULATION, 2002, 106 (23) :2913-2918
[25]   Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction - Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide [J].
Omland, T ;
Aakvaag, A ;
Bonarjee, VVS ;
Caidahl, K ;
Lie, RT ;
Nilsen, DWT ;
Sundsfjord, JA ;
Dickstein, K .
CIRCULATION, 1996, 93 (11) :1963-1969
[26]   Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment [J].
Omland, T ;
Aakvaag, A ;
VikMo, H .
HEART, 1996, 76 (03) :232-237
[27]   American Heart Association Guide for improving cardiovascular health at the community level - A statement for public health practitioners, healthcare providers, and health policy makers from the American Heart Association expert panel on population and prevention science [J].
Pearson, TA ;
Bazzarre, TL ;
Daniels, SR ;
Fair, JM ;
Fortmann, SP ;
Franklin, BA ;
Goldstein, LB ;
Hong, YL ;
Mensah, GA ;
Sallis, JF ;
Smith, S ;
Stone, NJ ;
Taubert, KA .
CIRCULATION, 2003, 107 (04) :645-651
[28]   Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease - Prospective analysis from the Women's Health Initiative observational study [J].
Pradhan, AD ;
Manson, JE ;
Rossouw, JE ;
Siscovick, DS ;
Mouton, CP ;
Rifai, N ;
Wallace, RB ;
Jackson, RD ;
Pettinger, MB ;
Ridker, PM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (08) :980-987
[29]   The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population [J].
Raymond, I ;
Groenning, BA ;
Hildebrandt, PR ;
Nilsson, JC ;
Baumann, M ;
Trawinski, J ;
Pedersen, F .
HEART, 2003, 89 (07) :745-751
[30]  
Raymond Ilan, 2002, HeartDrug, V2, P167, DOI 10.1159/000065944